VistaSeq Hereditary Cancer Panel without BRCA
81201; 81203; 81292; 81294; 81295; 81297; 81298; 81300; 81317; 81319; 81321; 81323; 81403; 81404(x2); 81405(x3); 81406(x4); 81408; 81479
The following genes are assessed: APC, ATM, BARD1, BMPR1A, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FAM175A, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRKAR1A, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53.
A Clinical Questionnaire for VistaSeq℠ should be submitted with specimens.
Lavender-top (EDTA) tube or yellow-top (ACD) tube
Maintain specimen at room temperature
Causes for Rejection
Frozen specimen; leaking tube; clotted specimen; grossly hemolyzed specimen; incorrect anticoagulant
The VistaSeq℠ Hereditary Cancer Panel Without BRCA provides an assessment of inherited genetic mutations within a panel of 25 genes known to be associated with hereditary cancer syndromes. The test is intended for individuals who have already had a BRCA1 and BRCA2 gene assessment, but for whom results of that testing were negative and/or personal or family history warrant assessment of additional genes.
Each gene sequence is interpreted independently of all other gene sequences. However, variants in different genes may sometimes interact to cause or modify a typically monogenic disease phenotype. It cannot be excluded that pathogenic variants were missed due to limitations inherent in the methodologies used here. In addition, the presence of an inherited cancer syndrome due to a different genetic cause can also not be ruled out. Any interpretation given here should be clinically correlated with available information about presentation and relevant family history of the patient.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Next generation sequencing, array-based comparative genomic hybridization (aCGH), and multiplex ligation-dependent probe amplification (MLPA) platforms. The entire coding regions, as well as all flanking noncoding regions, of 25 cancer genes known to be involved in the development and progression of cancers is analyzed by next generation sequencing. Flanking regions for all genes include +/– 20 bp and +/– 10 bp. Copy number variations are assessed by aCGH or MLPA to detect deletions and duplications. BRCA1 and BRCA2 genes are not included in this test.
Daly MB, Axilbund JE, Buys S, et al. Clinical practice guidelines in oncology. Genetic/familial high-risk assessment: Breast and ovarian. J Natl Compr Canc Netw. 2010 May; 8(5):562-594. PubMed 20495085
LaDuca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: Analysis of more than 2,000 patients. Genet Med. 2014 Nov; 16(11):830-837. PubMed 24763289
Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. Working Group of the American College of Medical Genetics and Genomics Laboratory Quality Assurance Committee. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013 Sep; 15(9):733-747. PubMed 23887774
Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer.2015 Jan 1; 121(1):25-33. PubMed 25186627